News
Obesity drugmaker Novo Nordisk NOVOb.CO on Wednesday cut its full-year sales and profit outlook amid lacklustre U.S. prescription data and posted first-quarter operating profit above analyst forecasts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback